Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

NCT03596866 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03596866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03596866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
April 19, 2019
Completion date
September 18, 2024
Enrollment
248 (actual)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

alk+ advanced nsclc